Meanwhile, conjugating CpG motifs, the ligand for Toll-like receptor (TLR9), to oligonucleotides, including siRNA, antisense against STAT3, enables targeted in vivo delivery into TLR9-positive tumor-associated immune cells as well as tumor cells with elevated TLR expression, leading to potent antitumor effects through both antitumor immune responses and direct tumor cell killing (21, 22). The gene discussed is TLR9; the disease is neoplasm.